Abstract
Liver-expressed antimicrobial peptide 2 (LEAP-2) is a newly identified peptide hormone involved in glucose metabolism. It acts as a noncompetitive antagonist of ghrelin hormone’s receptor. Polycystic ovary syndrome (PCOS) is a common metabolic and reproductive disease associated with insulin resistance. We aimed to compare circulating LEAP-2 levels in subjects with PCOS and controls. We also focused to determine whether there was a relationship between LEAP-2 and metabolic parameters in women with PCOS. We enrolled 64 subjects with PCOS and 64 age and body mass index (BMI)-matched controls into the current cross-sectional study. Circulating LEAP-2 and ghrelin levels were measured via ELISA method. Metabolic and hormonal parameters of the involved subjects were analyzed. We found that circulating LEAP-2 and ghrelin levels were decreased in women with PCOS as compared with controls. LEAP-2 showed a positively independent association with ghrelin while LEAP-2 exhibited an inverse association with insulin resistance, BMI, and free-androgen index (FAI). Additionally, subjects having the lowest tertile of LEAP-2 were in positive link of developing PCOS risk with respect to those subjects having the highest tertile of LEAP-2 levels. Decreased LEAP-2 levels were associated with a high possibility of having PCOS risk associated with insulin resistance.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
